ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status:
Withdrawn
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects and best dose of FT-2102 when given together
with ASTX727 in treating patients with IDH1-mutated myelodysplastic syndrome or acute myeloid
leukemia that has come back (recurrent) or does not respond to treatment (refractory).
ASTX727 is an oral deoxyribonucleic acid (DNA) methyltransferase (DNMT) inhibitor. DNA
methylation is necessary for cell differentiation and development. Changes to the methylation
profile can lead to DNA instability which can cause diseases like cancer. DNMT inhibitors
target and inhibit these changes. FT-2102 is an isocitrate dehydrogenase 1 (IDH1) inhibitor.
IDH1 is a type of protein involved in metabolism, or the process of providing the body's
cells with energy. FT-2102 may stop the abnormal IDH1 protein and may reduce 2-HG levels in
diseased cells to levels found in normal cells. Giving ASTX727 and FT-2102 may work better in
treating patients with myelodysplastic syndrome or acute myeloid leukemia compared to ASTX727
and FT-2102 alone.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborators:
Astex Pharmaceuticals Astex Pharmaceuticals, Inc. Forma Therapeutics, Inc.